Target intelligence / Profile preview

Dynamin

Molecular classification
Enzyme, GTPase, Membrane-associated protein, Mechanochemical enzyme
01

Overview

Dynamin is a large GTPase enzyme critical for the scission of budding vesicles from cellular membranes, particularly in clathrin-mediated endocytosis and synaptic vesicle recycling[1][5]. It is part of the dynamin superfamily, alongside proteins involved in membrane fusion and fission events in organelles such as mitochondria and peroxisomes[1][2]. Mammalian cells express multiple isoforms: Dynamin-1 (neuronal), Dynamin-2 (ubiquitous), and Dynamin-3 (testis/brain-specific), each adapted for specialized roles in vesicle trafficking[1]. Dynamin assembles into spirals around vesicle necks, and upon GTP hydrolysis, it constricts and induces membrane fission[1][3]. It plays a key role in coupling signal transduction (via receptor-mediated endocytosis), cellular trafficking, and cytoskeletal remodeling[4]. Pharmacological inhibitors such as Dynasore have enabled detailed dissection of its function but raise safety concerns due to the broad physiological roles of dynamin[1]. Dynamin has emerging significance as a therapeutic target in models of neurodegeneration, cancer, and infection, where abnormal trafficking or altered endocytosis is involved[1][5].

Other names
DNM1 (gene name for Dynamin-1)DNM2 (Dynamin-2)DNM3 (Dynamin-3)Dynamin superfamily proteinMechano-GTPase
02

Mechanism of action

Inhibition of GTPase activity Disruption of dynamin-mediated membrane scission

03

Biological functions

EndocytosisVesicle traffickingSynaptic vesicle recyclingOrganelle divisionCytokinesisMembrane fissionActin remodeling
04

Disease associations

Neurodegenerative diseaseCancerInfectionCardiovascular diseaseOther (impaired vesicle trafficking in genetic disorders, e.g., Charcot-Marie-Tooth disease with DNM2 mutations)
05

Safety considerations

On-target toxicity due to disruption of endocytosis in normal cellsInterference with synaptic vesicle recycling (potential neurotoxicity if inhibited systemically)
06

Interacting drugs

Dynasore

1 more in the full profile.

07

Biomarkers

DNM2 mutation (for Charcot-Marie-Tooth disease subtype)Dynamin overexpression (in some cancers, as a potential biomarker of proliferation)

Beyond the preview

Go deeper on Dynamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call